The STFC Hartree Centre is a partner in ADDoPT (Advanced Digital Design of Pharmaceutical Therapeutics), a four-year £20.4m project which aims to transform the UK pharmaceutical industry by enabling the future digital design of innovative medicine manufacturing processes.
Announced in January 2016 (link opens in a new window) (link opens in a new window), this pioneering collaboration between government, industry and academia hopes to tackle the challenge of getting new innovative medicines to market in the quickest and most cost-effective way possible to ensure the earliest access for patients.
This will be achieved through the development of advanced digital design techniques that that eliminate non-viable drug candidate formulations as early as possible, streamlining design, development and manufacturing processes.
Industrial pharmaceutical project partners such as Pfizer, GSK, AstraZeneca and Bristol-Myers Squibb will provide case studies, to which we can apply our expertise in supercomputing, big data analytics and computational chemistry. In this way we hope to develop more accurate digital design techniques that will enable more of the early R&D process to be carried out virtually, saving time and improving cost efficiency.
Adrian Toland and Christelle Gendrin from the STFC Hartree Centre explain how the ADDoPT project is aiming to address key challenges for the pharmaceutical industry.
For a full list of partners involved in the project, please see the full press release.
For more information, visit the ADDoPT website.
If you have a project idea in mind or are interested in finding out more about one of our projects, please contact us.